RxPONDER
Regimen
- Experimental
- Adjuvant chemotherapy followed by endocrine therapy for >=5 years.
- Control
- Endocrine therapy alone for >=5 years.
Population
Women with HR+/HER2- breast cancer, 1-3 positive axillary nodes, and Oncotype DX RS <=25, stratified by menopausal status.
Key finding
RxPONDER showed that postmenopausal women with 1-3 positive nodes and RS <=25 gain no chemotherapy benefit, while premenopausal women in the same group do benefit -- though part of that benefit likely reflects chemotherapy-induced ovarian suppression. Cited in NCCN BINV-N for node-positive gene expression decisions.
Source: PMID 34914339
Timeline
- Publication: 2021 Dec 16
Guideline citations
- NCCN BREAST